[HTML][HTML] Cross-linking ligation and sequencing of hybrids (qCLASH) reveals an unpredicted miRNA targetome in melanoma cells

I Kozar, D Philippidou, C Margue, LA Gay, R Renne… - Cancers, 2021 - mdpi.com
Simple Summary miRNAs are omnipresent short non-coding RNA molecules, which post-
transcriptionally fine-tune the expression of most protein-coding genes in health and …

[HTML][HTML] Concomitant antihyperalgesic and antitumor effects of gabapentin in a murine cancer pain model

BE Brito, MA García, YM De Gouveia… - International journal of …, 2021 - mdpi.com
Cancer pain may be the consequence of physical nerve compression by a growing tumor.
We employed a murine model to study whether gabapentin was able to regulate tumor …

[HTML][HTML] BRAF/EZH2 signaling represses miR-129-5p inhibition of SOX4 thereby modulating BRAFi resistance in melanoma

K Gebhardt, B Edemir, E Gross, L Nemetschke… - Cancers, 2021 - mdpi.com
Simple Summary Approximately 60% of all melanomas are associated with a constitutive
activating BRAF mutation. Inhibition of BRAF downstream signaling by targeted therapies …

miRNAs in melanoma: tumor suppressors and oncogenes with prognostic potential

M Wozniak, A Mielczarek, M Czyz - Current medicinal …, 2016 - ingentaconnect.com
MicroRNAs (miRNAs), which are small non-coding RNA molecules that post-
transcriptionally regulate the expression of target genes, control the vast majority of cellular …

[HTML][HTML] miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma

TM Grzywa, K Klicka, W Paskal, J Dudkiewicz… - PLoS …, 2020 - journals.plos.org
Despite significant development of melanoma therapies, death rates remain high.
MicroRNAs, controlling posttranscriptionally gene expression, play role in development of …

[HTML][HTML] Genetic layout of melanoma lesions is associated with BRAF/MEK-targeted therapy resistance and transcriptional profiles

E Vergani, A Busico, M Dugo, A Devecchi… - Journal of Investigative …, 2022 - Elsevier
The genetic landscape of melanoma resistance to targeted therapy with small molecules
inhibiting BRAF and MEK kinases is still largely undefined. In this study, we portrayed in …

[HTML][HTML] Current understanding of epigenetics role in melanoma treatment and resistance

M Karami Fath, A Azargoonjahromi, A Soofi… - Cancer cell …, 2022 - Springer
Melanoma is the most aggressive form of skin cancer resulting from genetic mutations in
melanocytes. Several factors have been considered to be involved in melanoma …

[HTML][HTML] Identification of microRNA–mRNA networks in melanoma and their association with PD-1 checkpoint blockade outcomes

RAS Sloane, MG White, RG Witt, A Banerjee… - Cancers, 2021 - mdpi.com
Simple Summary We conducted a network analysis of microRNA–mRNA associations in
melanoma tissue and cell lines to identify the microRNAs central to melanoma biology and …

Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells

I Kozar, G Cesi, C Margue, D Philippidou… - Biochimica et Biophysica …, 2017 - Elsevier
Background Melanoma is an aggressive skin cancer with increasing incidence worldwide.
The development of BRAF kinase inhibitors as targeted treatments for patients with BRAF …

Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies

M Rubatto, S Borriello, N Sciamarrelli, V Pala… - Melanoma …, 2023 - journals.lww.com
Melanoma is a rare but highly lethal type of skin cancer whose incidence is increasing
globally. Melanoma is characterized by high resistance to therapy and relapse. Despite …